Cetera Investment Advisers Grows Stake in The Cooper Companies, Inc. (NASDAQ:COO)

Cetera Investment Advisers lifted its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 1.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,049 shares of the medical device company’s stock after acquiring an additional 312 shares during the quarter. Cetera Investment Advisers’ holdings in Cooper Companies were worth $2,211,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. T. Rowe Price Investment Management Inc. increased its position in shares of Cooper Companies by 2.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,678,965 shares of the medical device company’s stock worth $705,928,000 after acquiring an additional 155,233 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Cooper Companies by 1.5% during the fourth quarter. JPMorgan Chase & Co. now owns 5,004,523 shares of the medical device company’s stock worth $460,066,000 after acquiring an additional 74,501 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Cooper Companies by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 4,906,463 shares of the medical device company’s stock worth $449,907,000 after acquiring an additional 109,907 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Cooper Companies by 14.6% during the fourth quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company’s stock worth $415,985,000 after acquiring an additional 574,899 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Cooper Companies by 517.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,529,477 shares of the medical device company’s stock worth $324,466,000 after acquiring an additional 2,957,421 shares during the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Stock Performance

Shares of COO stock opened at $82.92 on Monday. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The business has a 50 day moving average of $80.19 and a two-hundred day moving average of $90.00. The Cooper Companies, Inc. has a 52 week low of $69.81 and a 52 week high of $112.38. The company has a market cap of $16.58 billion, a P/E ratio of 42.52, a PEG ratio of 2.25 and a beta of 1.08.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, meeting analysts’ consensus estimates of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. As a group, analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on COO. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a report on Friday, March 7th. Citigroup lowered their price objective on Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a report on Friday, March 7th. Robert W. Baird lowered their price objective on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a report on Friday, March 7th. BNP Paribas raised Cooper Companies to a “hold” rating in a report on Thursday, March 13th. Finally, Stifel Nicolaus lowered their price objective on Cooper Companies from $115.00 to $105.00 and set a “buy” rating for the company in a report on Friday, March 7th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.25.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.